Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences

Paxlovid (nirmatrelvir plus ritonavir) is a new oral antiviral therapeutic for the treatment of COVID-19. Nirmatrelvir is an inhibitor of SARS-CoV-2 main protease, while ritonavir is used as a CYP3A inhibitor in low doses to slow the metabolism of nirmatrelvir, thus enhancing their therapeutic effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Azanza, José Ramón, Mensa, Josep, del Castillo, Juan González, Rufo, Manuel Linares, Molero, José María, Valle, Natalia Madero, Barberán, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333114/
https://www.ncbi.nlm.nih.gov/pubmed/35822605
http://dx.doi.org/10.37201/req/054.2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333114/
https://www.ncbi.nlm.nih.gov/pubmed/35822605
http://dx.doi.org/10.37201/req/054.2022

Ejemplares similares